Your browser doesn't support javascript.
loading
Targeting the deubiquitinase USP7 for degradation with PROTACs.
Murgai, Arunima; Sosic, Izidor; Gobec, Martina; Lemnitzer, Patricia; Proj, Matic; Wittenburg, Sophie; Voget, Rabea; Gütschow, Michael; Krönke, Jan; Steinebach, Christian.
Afiliação
  • Murgai A; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. jan.kroenke@charite.de.
  • Sosic I; German Cancer Consortium (DKTK) partner site Berlin and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Gobec M; Faculty of Pharmacy, University of Ljubljana, SI-1000, Ljubljana, Slovenia.
  • Lemnitzer P; Faculty of Pharmacy, University of Ljubljana, SI-1000, Ljubljana, Slovenia.
  • Proj M; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. jan.kroenke@charite.de.
  • Wittenburg S; Faculty of Pharmacy, University of Ljubljana, SI-1000, Ljubljana, Slovenia.
  • Voget R; Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, D-53121, Bonn, Germany. c.steinebach@uni-bonn.de.
  • Gütschow M; Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, D-53121, Bonn, Germany. c.steinebach@uni-bonn.de.
  • Krönke J; Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, D-53121, Bonn, Germany. c.steinebach@uni-bonn.de.
  • Steinebach C; Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. jan.kroenke@charite.de.
Chem Commun (Camb) ; 58(63): 8858-8861, 2022 Aug 04.
Article em En | MEDLINE | ID: mdl-35852517
ABSTRACT
Targeting deubiquitinating enzymes (DUBs) has emerged as a promising therapeutic approach in several human cancers and other diseases. DUB inhibitors are exciting pharmacological tools but often exhibit limited cellular potency. Here we report PROTACs based on a ubiquitin-specific protease 7 (USP7) inhibitor scaffold to degrade USP7. By investigating several linker and E3 ligand types, including novel cereblon recruiters, we discovered a highly selective USP7 degrader tool compound that induced apoptosis of USP7-dependent cancer cells. This work represents one of the first DUB degraders and unlocks a new drug target class for protein degradation.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Peptídeos e Proteínas de Sinalização Intercelular / Neoplasias Limite: Humans Idioma: En Revista: Chem Commun (Camb) Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Peptídeos e Proteínas de Sinalização Intercelular / Neoplasias Limite: Humans Idioma: En Revista: Chem Commun (Camb) Ano de publicação: 2022 Tipo de documento: Article